Company release, 3 February 2022 at 9:15 a.m. (EET)
Nightingale Health Plc (“Nightingale”) announced on 18 January 2022, that it has agreed on an acquisition where it purchases all shares of Finnish genetic testing company Negen Oy (“Negen”). The transaction was subject to certain conditions, which have been fulfilled and the transaction has been completed. Negen will be reported as part of Nightingale Health Group as of 3 February 2022.
For further information, please contact:
Teemu Suna, CEO
Oaklins Merasco Ltd, tel. +358 9 6129 670
Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. Our wide-ranging disease risk predictions consist of two interconnected factors: Our proprietary blood analysis technology and a large amount of data on health events. We help people make better personal health decisions and connect the health industry to offer their services for individuals’ preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.